# Mitomycin C

## Mitonco inj 10mg \(專案進口\)

| 藥物代碼 | IMIT2 |
| :--- | :--- |
| 適應症 | Treatment of disseminated adenocarcinoma of the stomach \(in combination with other chemotherapy agents\) and disseminated adenocarcinoma of the pancreas \(in combination with other chemotherapy agents\) and as palliative treatment when other modalities have failed. |
| 副作用 | Leukopenia, thrombocytopenia, anorexia, nausea/vomiting, malaise, weight loss, bleeding tendency & anemia. Haemolytic-uremic syndrome, microangiopathic hemolytic anemia, nephropathy, bone marrow depression, interstitial pneumonia, liver & biliary tract disorders. |
| 禁忌 | Hypersensitivity to mitomycin or any component of the formulation; thrombocytopenia; coagulation disorders, or other increased bleeding tendency |
| 藥物保存方式 | 攝氏30度C以下 |
| 用法用量 | Intermittent therapy Adult 4-6 mg IV once or twice weekly. Consecutive therapy Adult 2 mg IV once daily. Large dose intermittent therapyAdult 10-30 mg IV at 1-3 \(or more\) weeks intervals. Combined use with other antineoplastic agent Adult 2-4 mg once or twice weekly. Bladder cancer Prophylaxis of recurrence: 4-10 mg intravesically once daily or every 2 days. Treatment: 10-40 mg intravesically once daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest high risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Hold Breast Feeding 暫停哺乳 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IRR, IVD |
| 乾粉稀釋液 | IVD:以25mL無菌注射用水溶解 |
| 輸注點滴液 | 【N/S】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、腎功能。 |

